© Michal Jarmoluk

Drug shows greater effectiveness than Cisplatin

Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.

Based on a compound of the rare precious metal osmium and developed by researchers at the UK’s University of Warwick, FY26 is able to shut down a cancer cell by exploiting weaknesses inherent in their energy generation. The researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments, and has been shown to be active against cancer cells that have become resistant to platinum-based drugs. The investigation is part-funded by the European Research Council.

The experiments conducted by the Wellcome Trust Sanger Institute comprising 809 cancer cell lines found that FY26 was 49 times more potent than cisplatin. Similar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.

Commenting on the drug’s benefits when compared to existing platinum-based drugs, such as Cisplatin, lead researcher Professor Peter Sadler of the University of Warwick said: “Platinum-based drugs are used in nearly 50% of all chemotherapeutic regimens and exert their activity by damaging DNA, and cannot select between cancerous and non-cancerous cells. This can lead to a wide-range of side effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.

“Existing platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action remains active against cancer cells that have become resistant to drugs such as Cisplatin”.

The new drug works by forcing cancer cells to use their mitochondria, the ‘power house’ of a cell, to generate the energy necessary to function. Whilst healthy cells use mitochondria to generate energy, cancer cells contain defective mitochondria that are incapable of sustaining the cell’s energy requirements.

In the absence of FY26, cancer cells switch from using their defective mitochondria to using metabolic activity in their cytoplasm to generate energy. By stopping this switch of energy source, the drug causes the cancer cell to die.

The paper is published in full by PNAS.